Photopheresis in HIV-1 Infected Patients Utilizing Benzoporphyrin Derivative (BPD) Verteporfin and Light

Author(s): Zale P. Bernstein, Thomas Dougherty, Sandra Gollnick, Stanley A. Schwartz, Supriya D. Mahajan, James Kepner, Adam Sumlin, Carleton Stewart, Paul Wallace, Adaffaras Adal, Harold Walder, Bernard Poiesz.

Journal Name: Current HIV Research

Volume 6 , Issue 2 , 2008

Submit Manuscript
Submit Proposal

Abstract:

An ex vivo trial utilizing photopheresis with Benzoporphyrin Derivative as the photoactive compound, identified the minimum energy levels of light and concentrations of BPD that eradicated both cell-free and cell-associated HIV- 1 infectivity without destroying the virus particles or infected leukocytes. Leukocytes remained viable with altered chemokine/cytokine expression. Apoptosis was induced in a minority of CD4 but not CD8 positive cells with a statistically significant increase in cytolytic T-cell activity. In the 24 week clinical trial in 7 HIV-1 infected patients, three who had rapidly rising viral loads prior to initiating therapy stabilized. Two had a sustained greater than 0.5 log decrement and 5 had stable plasma viral loads (less than a 0.5 log increment or decrement) with varied effects on absolute CD4 and CD8 positive lymphocytes counts. One achieved a greater than 1 log decrement in HIV-1 plasma viral load and undetectable in vivo cell-free and cell-associated HIV-1 infectivity with an increased in vitro lymphocyte mitogen stimulation index. Under amended protocol, 5 additional 12 month courses were administered to three additional patients and two of the previous enrollees. Area under the curve for viral load showed a significant decrease from pre- to post-therapy (p 0.007). No associated toxicities were observed.

Keywords: HIV, photopheresis, benzoporphyrin, granzyme, chemokine

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 6
ISSUE: 2
Year: 2008
Page: [152 - 163]
Pages: 12
DOI: 10.2174/157016208783885001
Price: $58

Article Metrics

PDF: 1